Determinants of resistance and response to melanoma therapy.

Autor: Robertson BM; Department of Biochemistry and Molecular Biology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA., Fane ME; Department of Biochemistry and Molecular Biology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA., Weeraratna AT; Department of Biochemistry and Molecular Biology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA., Rebecca VW; Department of Biochemistry and Molecular Biology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA. vrebecc2@jh.edu.
Jazyk: angličtina
Zdroj: Nature cancer [Nat Cancer] 2024 Jul; Vol. 5 (7), pp. 964-982. Date of Electronic Publication: 2024 Jul 17.
DOI: 10.1038/s43018-024-00794-1
Abstrakt: Metastatic melanoma is among the most enigmatic advanced cancers to clinically manage despite immense progress in the way of available therapeutic options and historic decreases in the melanoma mortality rate. Most patients with metastatic melanoma treated with modern targeted therapies (for example, BRAFV600E/K inhibitors) and/or immune checkpoint blockade (for example, anti-programmed death 1 therapy) will progress, owing to profound tumor cell plasticity fueled by genetic and nongenetic mechanisms and dichotomous host microenvironmental influences. Here we discuss the determinants of tumor heterogeneity, mechanisms of therapy resistance and effective therapy regimens that hold curative promise.
(© 2024. Springer Nature America, Inc.)
Databáze: MEDLINE
Externí odkaz: